182 related articles for article (PubMed ID: 38273654)
21. Targeted deletion of BCL11A gene by CRISPR-Cas9 system for fetal hemoglobin reactivation: A promising approach for gene therapy of beta thalassemia disease.
Khosravi MA; Abbasalipour M; Concordet JP; Berg JV; Zeinali S; Arashkia A; Azadmanesh K; Buch T; Karimipoor M
Eur J Pharmacol; 2019 Jul; 854():398-405. PubMed ID: 31039344
[TBL] [Abstract][Full Text] [Related]
22. Reactivation of γ-globin in adult β-YAC mice after ex vivo and in vivo hematopoietic stem cell genome editing.
Li C; Psatha N; Sova P; Gil S; Wang H; Kim J; Kulkarni C; Valensisi C; Hawkins RD; Stamatoyannopoulos G; Lieber A
Blood; 2018 Jun; 131(26):2915-2928. PubMed ID: 29789357
[TBL] [Abstract][Full Text] [Related]
23. Molecular analysis of the erythroid phenotype of a patient with BCL11A haploinsufficiency.
Wessels MW; Cnossen MH; van Dijk TB; Gillemans N; Schmidt KLJ; van Lom K; Vinjamur DS; Coyne S; Kurita R; Nakamura Y; de Man SA; Pfundt R; Azmani Z; Brouwer RWW; Bauer DE; van den Hout MCGN; van IJcken WFJ; Philipsen S
Blood Adv; 2021 May; 5(9):2339-2349. PubMed ID: 33938942
[TBL] [Abstract][Full Text] [Related]
24. Reactivation of γ-globin expression using a minicircle DNA system to treat β-thalassemia.
Ma SP; Gao XX; Zhou GQ; Zhang HK; Yang JM; Wang WJ; Song XM; Chen HY; Lu DR
Gene; 2022 Apr; 820():146289. PubMed ID: 35143940
[TBL] [Abstract][Full Text] [Related]
25. Development and characterization of K562 cell clones expressing BCL11A-XL: Decreased hemoglobin production with fetal hemoglobin inducers and its rescue with mithramycin.
Finotti A; Gasparello J; Breveglieri G; Cosenza LC; Montagner G; Bresciani A; Altamura S; Bianchi N; Martini E; Gallerani E; Borgatti M; Gambari R
Exp Hematol; 2015 Dec; 43(12):1062-1071.e3. PubMed ID: 26342260
[TBL] [Abstract][Full Text] [Related]
26. Hemoglobin genetics: recent contributions of GWAS and gene editing.
Smith EC; Orkin SH
Hum Mol Genet; 2016 Oct; 25(R2):R99-R105. PubMed ID: 27340226
[TBL] [Abstract][Full Text] [Related]
27. CRISPR-Cas9 interrogation of a putative fetal globin repressor in human erythroid cells.
Chung JE; Magis W; Vu J; Heo SJ; Wartiovaara K; Walters MC; Kurita R; Nakamura Y; Boffelli D; Martin DIK; Corn JE; DeWitt MA
PLoS One; 2019; 14(1):e0208237. PubMed ID: 30645582
[TBL] [Abstract][Full Text] [Related]
28. Effects of Mithramycin on BCL11A Gene Expression and on the Interaction of the BCL11A Transcriptional Complex to γ-Globin Gene Promoter Sequences.
Finotti A; Gasparello J; Zuccato C; Cosenza LC; Fabbri E; Bianchi N; Gambari R
Genes (Basel); 2023 Oct; 14(10):. PubMed ID: 37895276
[TBL] [Abstract][Full Text] [Related]
29. Precision Editing as a Therapeutic Approach for β-Hemoglobinopathies.
Paschoudi K; Yannaki E; Psatha N
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298481
[TBL] [Abstract][Full Text] [Related]
30. Editing a γ-globin repressor binding site restores fetal hemoglobin synthesis and corrects the sickle cell disease phenotype.
Weber L; Frati G; Felix T; Hardouin G; Casini A; Wollenschlaeger C; Meneghini V; Masson C; De Cian A; Chalumeau A; Mavilio F; Amendola M; Andre-Schmutz I; Cereseto A; El Nemer W; Concordet JP; Giovannangeli C; Cavazzana M; Miccio A
Sci Adv; 2020 Feb; 6(7):. PubMed ID: 32917636
[TBL] [Abstract][Full Text] [Related]
31. Acyclovir induces fetal hemoglobin via downregulation of γ-globin repressors, BCL11A and SOX6 trans-acting factors.
Ali H; Khan F; Ghulam Musharraf S
Biochem Pharmacol; 2021 Aug; 190():114612. PubMed ID: 34010599
[TBL] [Abstract][Full Text] [Related]
32. BCL11A enhancer-edited hematopoietic stem cells persist in rhesus monkeys without toxicity.
Demirci S; Zeng J; Wu Y; Uchida N; Shen AH; Pellin D; Gamer J; Yapundich M; Drysdale C; Bonanno J; Bonifacino AC; Krouse AE; Linde NS; Engels T; Donahue RE; Haro-Mora JJ; Leonard A; Nassehi T; Luk K; Porter SN; Lazzarotto CR; Tsai SQ; Weiss MJ; Pruett-Miller SM; Wolfe SA; Bauer DE; Tisdale JF
J Clin Invest; 2020 Dec; 130(12):6677-6687. PubMed ID: 32897878
[TBL] [Abstract][Full Text] [Related]
33. Limitations of mouse models for sickle cell disease conferred by their human globin transgene configurations.
Woodard KJ; Doerfler PA; Mayberry KD; Sharma A; Levine R; Yen J; Valentine V; Palmer LE; Valentine M; Weiss MJ
Dis Model Mech; 2022 Jun; 15(6):. PubMed ID: 35793591
[TBL] [Abstract][Full Text] [Related]
34. Natural regulatory mutations elevate the fetal globin gene via disruption of BCL11A or ZBTB7A binding.
Martyn GE; Wienert B; Yang L; Shah M; Norton LJ; Burdach J; Kurita R; Nakamura Y; Pearson RCM; Funnell APW; Quinlan KGR; Crossley M
Nat Genet; 2018 Apr; 50(4):498-503. PubMed ID: 29610478
[TBL] [Abstract][Full Text] [Related]
35. ATF4 Regulates MYB to Increase γ-Globin in Response to Loss of β-Globin.
Boontanrart MY; Schröder MS; Stehli GM; Banović M; Wyman SK; Lew RJ; Bordi M; Gowen BG; DeWitt MA; Corn JE
Cell Rep; 2020 Aug; 32(5):107993. PubMed ID: 32755585
[TBL] [Abstract][Full Text] [Related]
36. ZNF410 represses fetal globin by singular control of CHD4.
Vinjamur DS; Yao Q; Cole MA; McGuckin C; Ren C; Zeng J; Hossain M; Luk K; Wolfe SA; Pinello L; Bauer DE
Nat Genet; 2021 May; 53(5):719-728. PubMed ID: 33859416
[TBL] [Abstract][Full Text] [Related]
37. Induction of therapeutic levels of HbF in genome-edited primary β
Mingoia M; Caria CA; Ye L; Asunis I; Marongiu MF; Manunza L; Sollaino MC; Wang J; Cabriolu A; Kurita R; Nakamura Y; Cucca F; Kan YW; Marini MG; Moi P
Br J Haematol; 2021 Jan; 192(2):395-404. PubMed ID: 33216968
[TBL] [Abstract][Full Text] [Related]
38. Dual function NFI factors control fetal hemoglobin silencing in adult erythroid cells.
Qin K; Huang P; Feng R; Keller CA; Peslak SA; Khandros E; Saari MS; Lan X; Mayuranathan T; Doerfler PA; Abdulmalik O; Giardine B; Chou ST; Shi J; Hardison RC; Weiss MJ; Blobel GA
Nat Genet; 2022 Jun; 54(6):874-884. PubMed ID: 35618846
[TBL] [Abstract][Full Text] [Related]
39. C2H2 Zinc Finger Transcription Factors Associated with Hemoglobinopathies.
Zhang X; Xia F; Zhang X; Blumenthal RM; Cheng X
J Mol Biol; 2024 Apr; 436(7):168343. PubMed ID: 37924864
[TBL] [Abstract][Full Text] [Related]
40. Development of a double shmiR lentivirus effectively targeting both BCL11A and ZNF410 for enhanced induction of fetal hemoglobin to treat β-hemoglobinopathies.
Liu B; Brendel C; Vinjamur DS; Zhou Y; Harris C; McGuinness M; Manis JP; Bauer DE; Xu H; Williams DA
Mol Ther; 2022 Aug; 30(8):2693-2708. PubMed ID: 35526095
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
